AxoGen Net Long-Term Debt 2010-2024 | AXGN
AxoGen net long-term debt from 2010 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
| AxoGen Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $15 |
| 2020 | $35 |
| 2019 | $0 |
| 2018 | $-23 |
| 2017 | $0 |
| 2016 | $-2 |
| 2015 | $N/A |
| 2014 | $-2 |
| 2013 | $N/A |
| 2012 | $16 |
| 2011 | $6 |
| 2010 | $4 |
| 2009 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.750B | $0.187B |
| AxoGen, Inc. engages in developing and marketing surgical solutions for peripheral nerves. The company's portfolio of products includes Avance Nerve Graft(R), AxoGuard Nerve Connector(R), AxoGuard Nerve Protector(R), Avive Soft Tissue Membrane(R), AcroVal Neurosensory & Motor Testing System(R) and AxoTouch Two-Point Discriminator(R). It operates primarily in the United States, Canada, the United Kingdom, and other European and international countries. AxoGen Inc., formerly known as AxoGen Corp., is based in FL, United States. | |||